InsidersTradesSigma
Track the Avalanche Biotechnologies, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was filed on 1 February 2016 (Attribution). Among the most active insiders: Wachter Paul. All data is accessible without an account.
Analysts rate Avalanche Biotechnologies, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
Avalanche Biotechnologies, Inc. is a biopharmaceutical company focused on developing gene therapies for treating eye diseases and other conditions. It is listed on the XNAS market.